GRAIL to Announce First Quarter 2025 Financial Results
Rhea-AI Summary
GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close.
The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss their financial performance and business progress. Interested parties can access the live webcast through GRAIL's investor relations website at investors.grail.com.
To participate, attendees should:
- Register via https://grail-q1-financial-results-2025.open-exchange.net/
- Connect at least ten minutes before the scheduled start
- Access the investor relations section for live and recorded webcasts
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GRAL declined 6.28%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
First Quarter 2025 Webcast and Conference Call Details
A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com.
Please register for the live event at https://grail-q1-financial-results-2025.open-exchange.net/.
To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-announce-first-quarter-2025-financial-results-302441708.html
SOURCE GRAIL, Inc.